Cargando…

N6-methyladenosine participates in mouse hippocampus neurodegeneration via PD-1/PD-L1 pathway

Developmental abnormalities and hippocampal aging leads to alteration in cognition. In the brain, N6-methyladenosine (m(6)A) is a common and reversible mRNA alteration that is essential for both neurodevelopment and neurodegeneration. However, its function in the postnatal hippocampus and the specif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Wen, Xie, Hongbo, Zeng, Yubing, Pei, Pei, Zhan, Xiaojun, Wang, Shan, Wang, Zhenlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206131/ https://www.ncbi.nlm.nih.gov/pubmed/37234260 http://dx.doi.org/10.3389/fnins.2023.1145092

Ejemplares similares

The N6‐methyladenosine RNA landscape in the aged mouse hippocampus
por: Huang, He, et al.
Publicado: (2022)

N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
por: Shi, Yanlong, et al.
Publicado: (2023)

Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer
por: Xue, M. Q., et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Maoxi, Zhong, et al.
Publicado: (2021)

Emerging Roles of N6-Methyladenosine Modification in Neurodevelopment and Neurodegeneration
por: Shu, Liqi, et al.
Publicado: (2021)

Overexpression of PD‐L1 causes germ cells to slough from mouse seminiferous tubules via the PD‐L1/PD‐L1 interaction
por: Fang, Lian, et al.
Publicado: (2022)

Comprehensive analysis of N6-methyladenosine-related RNA methylation in the mouse hippocampus after acquired hearing loss
por: Zhou, Xuehua, et al.
Publicado: (2023)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
por: Wang, Fengling, et al.
Publicado: (2023)

A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
por: Sun, Xin, et al.
Publicado: (2018)

Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer
por: Jiang, Ziting, et al.
Publicado: (2021)

Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer: A meta-analysis
por: Zhang, Pei-Pei, et al.
Publicado: (2021)

Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
por: Yang, Xiaojun, et al.
Publicado: (2022)

The changes in peripheral blood Th17 and Treg ratios in Hashimoto’s thyroiditis are accompanied by differential PD-1/PD-L1 expression
por: Fang, Jun, et al.
Publicado: (2022)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer
por: Wan, Weijun, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2020)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
por: Chen, Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_di59oiopqa1rqjkuqak5tg0pi8